Development of bifurcated curved bio-tube for the aorta with in-body tissue architecture

开发具有体内组织结构的主动脉分叉弯曲生物管

• 批准号: 21H03819
• 负责人: 首藤 敬史
• 金额: $ 11.48万
• 依托单位: Oita University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2021
• 资助国家: 日本
• 起止时间: 2021-04-01 至 2024-03-31
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-21H03819/
• 关键词: 再生医療; 大動脈手術; 血流解析; 人工血管; 代用臓器; 大動脈; 大血管; 移植; 分枝; 生体内組織形成術

生体内組織形成術（in-body tissue architecture)技術を用いて実際の臨床応用を想定し分岐管状の材料を得る鋳型の最適設計を行い、移植実験によって自己組織化し生着する再生能力、耐久性を調べ、待望の成長可能な「再生型自己代用分枝付き大動脈（バイオチューブ）」の安全な臨床応用へと繋げる実験を行った。T字型鋳型を設計作成し、成ヤギ皮下に埋植し二ヵ月後取出しバイオチューブ生成状態を確認した。不完全生成、欠損部等なく物理強度は十分満足するものであった。また組織学的分析では炎症細胞の浸潤なく、ほぼ１００％コラーゲンで構成されていた。ヤギに対する弓部置換方法を確立するため４頭の他の研究に使用したヤギを用いて予備実験を行った。安全性を確認後この取り出したバイオチューブを用いて同じヤギに対して脳分離体外循環下に弓部置換を行った。8頭に対して行ったが体外循環の負荷のためか最初の4頭は血胸、心不全等の術後合併症にて1週間以内に死亡した。その後は手技も安定し、術後合併症はおこらなくなったが、１頭は2週間後バイオチューブの穿孔で死亡した。残り3頭は現在生存中である。正常大動脈の血流、血圧データと造影CTデータから４D血流解析を行うと頭部分枝分岐直後の前壁から小弯側にかけてshear stressが高い部分が生じていたが、破裂した1頭の破裂部位はそのストレス部分に近く、なんらかの物理ストレスと破裂が関係したことが示唆された。弓部移植後の初期データは現在解析中である。

Tissue formation technology (in-body tissue architecture) technology in vivo is used in the field of tissue formation technology. The use of bifurcation tubular materials in tissue formation technology in vivo (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology (tissue formation technology) technology in vivo tissue formation technology in vivo The growth of the waiting list may lead to the use of a regenerative branch to pay for a large operation on its own behalf. A safe bed may be used for a safe operation. The T-shaped device was designed and implanted two months later, and two months later, the device was removed to generate a status confirmation device. The physical strength of incomplete generation, under-production and so on is very high. According to the histological analysis, the inflammatory cells were immersed and 100% of the cells were infected. The method of bow placement is to make sure that he studies the use of the bow to the equipment. After the safety is verified, you can use the same device to separate the body around the lower bow. 8-month-old after the first 4-year-old hemothorax, heart insufficiency and other symptoms, the death rate was within 1 year. After treatment, the hand is stable, the post-syndromes are stable, the post-syndromes are tranquilized, and the perforations are dead after 1-2-year-old. The handicapped man is still alive. Normal blood flow, blood flow imaging, CT blood flow analysis, 4D blood flow analysis, partial branch bifurcation, front wall, small bend, shear stress, high part, rupture part, physical part, front wall, back wall, front wall, front wall, front The early stage of arch transplantation is now in the process of analysis.